New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more: The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
via Google News
The Latest on: Glioblastoma
- Incysus technology to treat brain cancer heads to Phase I trial at UABon February 27, 2020 at 11:43 am
Incysus Therapeutics, a local biopharmaceutical company focused on developing cancer treatments, has initiated a Phase I clinical study of a new brain cancer treatment. The trial for the drug ...
- Insilico Medicine taps GSK alum for a six-month AI sprint aimed at brain canceron February 27, 2020 at 9:29 am
George Okafo will join Insilico as an entrepreneur-in-residence, as the company looks to wield its artificial intelligence networks and generative engines to uncover novel targets and molecules for ...
- Brain imaging may help predict when liquid biopsy will benefit individual glioblastoma patientson February 27, 2020 at 3:55 am
Tracking brain cancer with a blood test instead of a surgical biopsy may greatly improve quality of life for glioblastoma (GBM) patients and provide critical information for their care, but it is not ...
- Imaging can guide whether liquid biopsy will benefit individual glioblastoma patientson February 27, 2020 at 2:09 am
PHILADELPHIA - Tracking brain cancer with a blood test instead of a surgical biopsy may greatly improve quality of life for glioblastoma (GBM) patients and provide critical information for their care, ...
- Recurrent Glioblastoma Multiforme (GBM) Treatment Market 2020 Driven Increasing Demand and Opportunity Assessment, 2020-2024on February 26, 2020 at 10:28 pm
The Global "Recurrent Glioblastoma Multiforme (GBM) Treatment Market Report" gives a clear understanding of the current market situation which includes of antique and projected upcoming market size ...
- Targeting stromal cells may help overcome treatment resistance in glioblastomaon February 26, 2020 at 12:19 pm
The deadly brain cancer glioblastoma (GBM) is often resistant to chemotherapy and radiation, but new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson ...
- How targeting tumor blood vessels may help overcome treatment resistance in glioblastomaon February 26, 2020 at 11:00 am
Widely used drugs directed against VEGF or VEGFR inhibit this process. Unfortunately, though, those drugs have failed to rein in the aggressive brain cancer glioblastoma. Now scientists at the ...
- Surveillance after surgery does not improve outcomes for patients with glioblastomaon February 26, 2020 at 8:17 am
Glioblastoma is an aggressive and deadly brain cancer. Although improved treatment protocols have doubled the survival rate over the past 20 years, glioblastoma tumors usually grow back. After ...
- Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cellson February 26, 2020 at 1:58 am
Glioblastoma (GBM) is the most prevalent primary malignant brain tumor and is associated with extensive tumor cell infiltration into the adjacent brain parenchyma. However, there are limited targeted ...
- 1ST Biotherapeutics and twoXAR Advance Three Novel Glioblastoma Treatment Candidates into In Vivo Testing in Less Than One Yearon February 25, 2020 at 4:47 pm
Glioblastoma is the most common and most aggressive primary malignant brain tumor and developing effective treatments for this complex cancer has been historically difficult. It presents unique ...
via Bing News